Spironolactone and hair loss: what the studies found, and what people reported

Spironolactone (brand name Aldactone, “spiro” on forums) is a blood-pressure and heart-failure pill that also blocks androgens, the hormones behind pattern hair loss. Dermatologists prescribe it off-label for hair loss in women, and it is part of many trans women’s hormone therapy. This page puts the evidence next to what was said in 223 reddit threads (2014–2026) whose title names spironolactone, spiro or Aldactone: does it help, does it cause shedding, what side effects people had, and whether men can use it.

In short: the US label approves spironolactone for heart failure, high blood pressure, fluid build-up and an adrenal condition, not for hair loss. For women, the evidence is a mix of small studies: in an open 2005 study of 80 women on spironolactone or cyproterone acetate (another anti-androgen), 44% regrew hair and 44% held steady, with no placebo group; the one placebo-controlled trial (48 women, all also on minoxidil) found a bigger improvement on photos with spironolactone (38% vs 9%), but its hair-count difference fell just short of statistical significance. Irregular periods were the most common side effect. The studies are almost all in women; a 2023 review links that to breast growth, lower libido and impotence in men on the pill. Topical spironolactone has a few small studies with mixed results. On reddit, of 124 people who described their own use, 27 said it helped their hair, 24 saw no change and 8 said their loss got worse; the rest had just started or didn’t say.

What the label and the studies say

The label first, then the studies in women (oral), the reviews, the topical studies, safety, and two papers on PCOS and on transgender patients.

ALDACTONE (spironolactone) tablets: US prescribing information

Pfizer · DailyMed (US National Library of Medicine), label version 25 (December), 2025 · The official US label of the original brand. It lists the uses the FDA approved it for: heart failure, high blood pressure, fluid build-up (edema) in liver cirrhosis or nephrotic syndrome, and primary hyperaldosteronism. Hair loss, acne and PCOS are not among them: for hair, spironolactone is prescribed off-label. Its warnings and side-effect figures come mostly from heart-failure patients, an older and sicker group than the women who take it for hair. Archived as the full label text from the DailyMed XML.

  • The approved uses are heart, blood-pressure, fluid and adrenal conditions; hair loss is not one of them. “ALDACTONE is an aldosterone antagonist indicated for:”
  • First listed: heart failure. “The treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure”
  • It raises potassium. The label says not to use it with high potassium, Addison's disease or eplerenone. “ALDACTONE is contraindicated in the patients with: • Hyperkalemia • Addison's disease • Concomitant use of eplerenone”
  • The label tells doctors to check potassium within a week of starting or raising the dose, and regularly after that. “Monitor serum potassium within 1 week of initiation or titration of ALDACTONE and regularly thereafter.”
  • Breast growth in men (gynecomastia): about 9% of men in a heart-failure trial at an average of 26 mg a day; more likely at higher doses, usually reversible. “ALDACTONE can cause gynecomastia. In RALES, patients with heart failure treated with a mean dose of 26 mg of spironolactone once daily, about 9% of the male subjects developed gynecomastia. The risk of gynecomastia increases in a dose-dependent manner with an onset that varies widely from 1–2 months to over a year. Gynecomastia is usually reversible.”
  • Hormonal side effects reported in trials or after approval include lower libido, erection problems, irregular or missed periods, and breast and nipple pain. “Decreased libido, inability to achieve or maintain erection, irregular menses or amenorrhea, postmenopausal bleeding, breast and nipple pain.”
  • Hair loss (alopecia) itself is on the label's list of skin reactions reported with it, with no frequency given. “Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), drug rash with eosinophilia and systemic symptoms (DRESS), alopecia, pruritis.”
  • For that list the label says the frequency and whether the drug caused it can't always be established. “Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency, reliably, or to establish a causal relationship to drug exposure.”
  • Pregnancy: because it blocks androgens, it may affect the sex development of a male fetus; the label says to avoid it in pregnancy or explain that risk. “Because of the potential risk to the male fetus due to anti-androgenic properties of spironolactone and animal data, avoid spironolactone in pregnant women or advise a pregnant woman of the potential risk to a male fetus.”
  • The label also describes tumours in rats given high doses for 18-24 months. “Orally administered ALDACTONE has been shown to be a tumorigen in dietary administration studies performed in Sprague Dawley rats, with its proliferative effects manifested on endocrine organs and the liver.”

Treatment of female pattern hair loss with oral antiandrogens

Sinclair R, Wewerinke M, Jolley D · Br J Dermatol, 2005 · The study most often cited for spironolactone in women. 80 women at one clinic in Melbourne, photographed before and after at least 12 months of treatment: 40 on spironolactone 200 mg a day, 40 on cyproterone acetate. No placebo group, not randomised; the photos were judged by three clinicians who didn't know the patient or the drug. The results of the two drugs were pooled, so there is no spironolactone-only figure. PubMed abstract; funding not stated in it.

  • Half of the women took spironolactone 200 mg a day, the other half cyproterone acetate, for at least 12 months. “Forty women received spironolactone 200 mg daily and 40 women received cyproterone acetate, either 50 mg daily or 100 mg for 10 days per month if premenopausal.”
  • With both drugs together: 44% regrew hair, 44% had no clear change and 12% kept losing hair. “Thirty-five (44%) women had hair regrowth, 35 (44%) had no clear change in hair density before and after treatment, and 10 (12%) experienced continuing hair loss during the treatment period.”
  • The authors say a placebo-controlled study is needed, because without one you can't tell this apart from how the hair loss would have gone anyway. “A placebo-controlled study is required to compare this outcome to the natural history of FPHL.”

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot study

Werachattawatchai P, Khunkhet S, Harnchoowong S, Lertphanichkul C · Int J Womens Dermatol, 2025 · The only placebo-controlled, double-blind trial of oral spironolactone for hair loss we found. 48 Thai women aged 21 to 45, spironolactone 100 mg or a dummy pill for 24 weeks; everyone also used 3% minoxidil, so it tests spironolactone added to minoxidil, not on its own. The authors call it a pilot and say the group was small. Funded by the authors' own university (Srinakharinwirot University); no conflicts declared. Open-access full text read.

  • Both groups used minoxidil, so nobody went untreated. “Forty-eight women aged 21 to 45 years were randomly assigned to receive spironolactone 100 mg or matched placebo once daily for 24 weeks. Twice-daily minoxidil 3% solution was used for all to avoid untreated participants.”
  • Hair counts rose more with spironolactone (9.5 vs 5.3 more thick hairs per cm²), but that difference was not statistically significant (P = .063). More women on it were rated as clearly improved on photos: 38% vs 9%. “The spironolactone group also showed greater moderate-to-marked improvement than the placebo group (38% vs 9%;”
  • The authors think the trial may have been too small or too short: spironolactone is said to need about a year to show. “This might be from underpowered statistics due to an insufficient sample size or a short duration of treatment as spironolactone use for FPHL was mentioned to require a year for noticeable improvements.”
  • In the trial's own words, the most common side effects were irregular periods (37.5%), painful periods (12.5%) and dizziness (8%). “The most common side effect was menstrual irregularities (37.5%), followed by dysmenorrhea (12.5%), and dizziness (8%).”
  • Half the women on spironolactone had a side effect, mostly period changes; 2 of 24 stopped because of irregular periods, which returned to normal within 3 months of stopping. “All participants were willing to continue medication, except for 2 participants (8%) who were concerned about irregular periods and requested study termination. The participants’ periods entirely returned to normal within 3 months after discontinuing spironolactone.”
  • Potassium: two women on spironolactone and one on placebo had a mildly high reading at week 24, which was normal again on retesting. “mild transient hyperkalemia without any symptoms occurred in 2 participants (9.5%) in the spironolactone group and 1 participant (4.5%) in the placebo group at week 24.”
  • Women not using adequate contraception, and women on hormonal birth control, could not take part. “inadequate contraception or use of hormonal contraceptives”

Spironolactone vs. bicalutamide in female pattern hair loss: a randomized clinical trial

Jha AK, Zeeshan M, Singh A, Ankad BS · Clin Exp Dermatol, 2026 · 204 women in India, randomised and double-blind, spironolactone 100 mg vs bicalutamide 50 mg for 24 weeks, each on its own. The largest randomised trial with a spironolactone arm we found, but there is no placebo group, so it compares the two drugs rather than showing either works. Registered (CTRI/2024/01/062101). PubMed abstract only; funding not stated in it.

  • Hair counts rose in both groups, more with bicalutamide. “The mean (SD) increase in hair count at the frontal site was 5.05 (3.61) hairs cm-2 in the bicalutamide group vs. 3.13 (2.62) hairs cm-2 in the spironolactone group”
  • Side effects were reported by 18.6% on spironolactone and 11.7% on bicalutamide. “Adverse events were reported in 18.6% of spironolactone-treated and 11.7% of bicalutamide-treated participants.”
  • On the clinical measures (photos, shedding score) the two drugs did not differ significantly. “Bicalutamide produced greater trichoscopic improvements than spironolactone; however, no significant between-group differences were observed in clinical endpoints.”

The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral finasteride in women with androgenic alopecia, female and male hair loss patterns: A blinded randomized clinical trial

Sadeghzadeh Bazargan A, Tavana Z, Dehghani A, Jafarzadeh A, Tabavar A, Alavi Rad E, Goodarzi A · J Cosmet Dermatol, 2024 · 60 women in Iran, minoxidil 2% plus either spironolactone 100 mg or finasteride 5 mg a day (the finasteride dose is five times the usual hair-loss dose), followed for 4 months. Called blinded and randomised in its title; no placebo group. PubMed abstract only; funding not stated in it.

  • Everyone used minoxidil; half added spironolactone, half finasteride. “The patients were divided into two groups receiving spironolactone 100 mg/day and finasteride 5 mg/day. In addition, a 2% minoxidil solution was used in all patients in addition to treatment with finasteride or spironolactone.”
  • At 4 months the spironolactone group did better on the doctors' rating. “the drugs used were ineffective in 6.7% of cases in the minoxidil-spironolactone group and in 16.7% of cases in the minoxidil-finasteride group.”
  • For women with the typical female pattern, the difference was not statistically significant. “The response to treatment in female pattern hair loss (FPHL) was not statistically significant (p: 0.52)”

The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review

Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W · Clin Cosmet Investig Dermatol, 2023 · A systematic review: 7 studies, 618 patients (553 women, 65 men), only two of them randomised trials. Every oral-spironolactone study was in women; the men were only in the topical studies. The authors could not pool the results into one number. Funded by the National Natural Science Foundation of China; no conflicts declared. Open-access full text read.

  • Seven studies, 618 patients, 414 of them on spironolactone. “We retrieved 784 papers and ultimately 7 articles matched our inclusion criteria and comprised 618 AGA patients (65 men, 553 women), 414 of them received spironolactone treatment.”
  • Most oral doses were 80 to 110 mg a day; the topical forms were 1% gels and 5% solutions. “Oral spironolactone doses ranged from 25mg to 200mg daily, with the vast majority between 80mg and 110 mg. Dosage forms for topical spironolactone use include gels of 1% and solutions of 5% twice daily.”
  • Side effects of oral spironolactone in these studies: period changes 7.9%, dizziness or headache 6.5%, facial hair 4.1%, rash 2.3%, high potassium 0.9%; 3.2% stopped because of them. “the most common side effects of oral spironolactone reported as menstrual disorder (7.9%), dizziness or headache (6.5%), facial hypertrichosis (4.1%), rash (2.3%) and hyperkalemia (0.9%), most of them are endurable and self-resolving, few patients (only 3.2%) discontinued spironolactone because of side effects.”
  • Why the studies are almost all in women: the authors point to breast growth, lower libido and impotence in men on oral spironolactone. “However, the vast majority of these studies recruited female participants, this may be related to the fact that side effects such as gynecomastia, decreased libido and relative impotence caused by hyperestrogenemia are more pronounced after using oral spironolactone in men,”
  • Topical spironolactone had fewer side effects; the authors see it as an option for men and women. “Topical spironolactone is safer than oral administration and is suitable for both male and female patients”
  • They still call minoxidil and finasteride the main treatments, and ask for better trials. “it must be stated that traditional therapies as topical minoxidil and oral finasteride still remain dominant and invaluable”

The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis

Aleissa M · Cureus, 2023 · A meta-analysis of trials and observational studies of oral spironolactone in women, by a single author (most reviews have two or more people checking the data). The abstract doesn't say how many studies or women were included, and reports strong differences between studies. No competing interests declared. PubMed abstract.

  • About 57% of women improved overall: more when spironolactone was combined with another treatment (66%) than alone (43%). “The overall rate of improved hair loss was 56.60%, with a higher rate of improvement (65.80%) observed in the combined therapy group compared to the monotherapy group (43.21%).”
  • For about 38% there was no or only modest improvement. “hair loss did not improve or showed a modest improvement in 37.80% of all patients.”
  • Side effects reported in at least two studies included scalp itch or flaking, period changes and facial hair. “The rates of adverse events reported in at least two studies were scalp pruritus or increased scurf (18.92%), menstrual disorders (11.85%), facial hypertrichosis (6.93%), and drug discontinuation (2.79%).”

Interventions for female pattern hair loss

van Zuuren EJ, Fedorowicz Z, Schoones J · Cochrane Database Syst Rev, 2016 · The Cochrane review of every randomised trial of female pattern hair loss treatments up to July 2015: 47 trials, 5,290 women. It found good enough evidence only for topical minoxidil, and listed spironolactone among the widely used treatments that still needed trials. Searches end in 2015, so the 2025-2026 trials above came later. No conflicts declared. PubMed abstract.

  • Evidence supported topical minoxidil. “there was evidence to support the efficacy and safety of topical minoxidil in the treatment of FPHL (mainly moderate to low quality evidence).”
  • Spironolactone was named among widely used treatments still needing randomised trials. “Further randomised controlled trials of other widely-used treatments, such as spironolactone, finasteride (different dosages), dutasteride, cyproterone acetate, and laser-based therapy are needed.”

Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: A Comparative, Clinical, and Trichoscopic Study

Hassan GFR, Elsaftawy RE, Mady OY, Gheida SF · Int J Trichology, 2025 · Topical: 80 women in Egypt, 1% spironolactone gel or 5% minoxidil gel for 6 months, 40 each. The abstract calls it a 'simple randomized' comparison; no placebo group, and it does not say it was blinded. No conflicts declared. PubMed abstract.

  • The 1% spironolactone gel group was compared with a 5% minoxidil gel group. “Group (A): was subjected to topical spironolactone 1% gel application for 6 months, twice. Group (B): was subjected to topical minoxidil 5% gel application for 6 months, twice daily.”
  • The improvement grades in the two groups were nearly the same. “In Group A: 10 patients had mild, 16 patients had moderate, two patients had excellent, and 12 had marked improvement. In Group B: 10 patients had mild, 14 patients had moderate, two patients had excellent, and 14 had marked improvement.”

Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment

Al Sayed NM, El Morsy EH, Hussein TM, Hassan EM · Dermatol Pract Concept, 2025 · Topical: 45 women in Egypt, three groups of 15 (finasteride 1%, spironolactone 5% or minoxidil 5% solution) for 16 weeks. Small and short; the abstract doesn't say it was randomised or blinded, and there is no placebo group. No competing interests declared. PubMed abstract.

  • With 5% spironolactone solution the scalp images showed no change after 16 weeks. “No trichoscopic changes were detected in group B.”
  • Topical finasteride and minoxidil did better than topical spironolactone in this study. “Both treatments showed greater effectiveness clinically and trichoscopically than topical spironolactone.”

Safety and tolerability of combination oral spironolactone and low-dose oral minoxidil for hair loss in adult females: A retrospective cohort study

Dewey E, Salloum L, Gregoire S, McIntosh BA, Zhao V, Mostaghimi A · J Am Acad Dermatol, 2026 · A look back through the records of 432 women taking spironolactone together with low-dose oral minoxidil for hair loss (Boston). It counts side effects; it does not measure hair, and it has no comparison group. The senior author reports consulting fees from and equity in several companies, including Hims & Hers Health and Pfizer (Aldactone's maker); the other authors declare none. PubMed abstract.

  • About 38% had a side effect; the most common were extra body or facial hair (from the minoxidil) and dizziness or light-headedness. “Adverse effect incidence was 37.7% (n = 163). Hypertrichosis was most common (n = 53, 12.3%) followed by dizziness/lightheadedness/orthostasis (n = 52, 12.0%).”
  • Taking other blood-pressure-lowering drugs as well was linked to about three times the odds of dizziness on standing. “Concurrent use of ≥1 additional blood pressure-altering medications increased orthostatic effects risk (odds ratio: 3.29; 95% confidence interval: 1.65-6.58; P = .001).”

Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne

Plovanich M, Weng QY, Mostaghimi A · JAMA Dermatol, 2015 · Not about hair: 974 healthy young women taking spironolactone for acne, records from two US hospitals, 2000-2014. Included because the label's potassium warning comes from heart-failure patients, and this is the large study of potassium in the young, healthy women who also take it for hair. Retrospective, no control group on the drug's effect. PubMed abstract; funding not stated in it.

  • High potassium was no more common on spironolactone (0.72% of tests) than the usual rate in these women (0.76%). “There were 13 abnormal serum potassium measurements in 1802 measurements obtained among young women receiving spironolactone therapy, yielding a hyperkalemia rate of 0.72%, equivalent to the 0.76% baseline rate of hyperkalemia in this population.”
  • The authors concluded that routine potassium tests aren't needed for healthy women taking it for acne. That is their conclusion for that group, not the label's. “Routine potassium monitoring is unnecessary for healthy women taking spironolactone for acne.”

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee

Carmina E, Azziz R, Bergfeld W, Escobar-Morreale HF, Futterweit W, Huddleston H, Lobo R, Olsen E · J Clin Endocrinol Metab, 2019 · Recommendations from an expert task force of the Androgen Excess and PCOS Society (dermatology, endocrinology, reproductive endocrinology), based on studies published to 2017. Expert opinion with graded evidence, not new data. PubMed abstract; funding and conflicts not stated in it.

  • Hair loss of this pattern alone, with normal hormone levels, should not be taken as a sign of too many androgens. “Isolated FPHL should not be considered a sign of hyperandrogenism when androgen levels are normal.”
  • But every woman with it should be checked for androgen excess (PCOS is the common cause). “In all patients with FPHL, assessment of a possible androgen excess is mandatory.”
  • Their advice: start with minoxidil, and add an antiandrogen (the group spironolactone belongs to) or a 5-alpha-reductase inhibitor for severe loss or high androgens. “Treatment of FPHL should start with minoxidil (5%), adding 5α-reductase inhibitors or antiandrogens when there is severe hair loss or hyperandrogenism.”

Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics

Gao JL, Streed CG Jr, Thompson J, Dommasch ED, Peebles JK · J Am Acad Dermatol, 2023 · A narrative review (authors from the Fenway Institute, Boston University and others) of hair-loss treatments for transgender and gender-diverse patients. The authors note there is little research in this group; their options are drawn from studies in cisgender patients. No conflicts declared. PubMed abstract.

  • The authors say there is little research on pattern hair loss in transgender and gender-diverse people. “Although gender-affirming hormone therapies affect hair growth, there is little research about AGA in TGD populations.”
  • They list spironolactone 200 mg a day as a first-line option for transfeminine patients. “Spironolactone 200 mg daily is also first-line for transfeminine patients.”
  • And they advise the dermatologist to coordinate with the hormone prescriber. “Dermatologists should coordinate care with the patient's primary gender-affirming clinician(s) so that shared knowledge of all medications exists across the care team.”

Male and female pattern hair loss

Iyengar L, Li J · Aust Prescr, 2025 · A practical review for prescribers in Australia (University of Melbourne authors). It lists spironolactone under treatments for female pattern hair loss only; for men it lists minoxidil and finasteride or dutasteride. One author reports payments from Bristol Myers Squibb and CeraVe unrelated to spironolactone. Open-access full text read.

  • Spironolactone is listed for women; for men the review lists minoxidil and 5-alpha-reductase inhibitors. “Pharmacological treatments for female pattern hair loss include minoxidil (topical and oral) and antiandrogens such as spironolactone. For male pattern hair loss, minoxidil and 5-alpha-reductase inhibitors (e.g. finasteride, dutasteride) can be used.”
  • Its suggested dose: start at 25 mg a day and go up slowly, with kidney-function checks, to at most 100 mg. “Generally started at 25 mg daily orally, and slowly up-titrated with renal function monitoring to a maximum dose of 100 mg daily.”
  • Results are usually visible after about 6 months. “It prevents hair loss effectively in the majority of patients and results in hair growth that is generally noticeable after 6 months.”
  • Side effects it names: high potassium (mainly with kidney or heart failure), low blood pressure, peeing more, low energy, irregular periods. “Hypotension, increased urinary frequency, low energy and irregular menstruation are other potential adverse effects.”
  • Not in pregnancy; it encourages co-prescribing contraception. “Contraception should be highly encouraged in women of childbearing potential and co-prescribed if possible.”
  • Finasteride and dutasteride, by contrast, are generally not recommended for women who could still become pregnant. “This treatment is generally not recommended in premenopausal women due to the risk of feminisation of the male fetus.”

Quotes are copied from the label on DailyMed (US National Library of Medicine) and from the abstracts and open-access full texts on PubMed and PubMed Central, checked 17 Oct 2026. Things to weigh: only one trial compared spironolactone with a placebo, and it had 48 women and lasted 24 weeks; the other trials compare it with another drug, so they can’t show how much it does on its own. Most studies are small, single-centre and in women; the men in the review only used it on the scalp. The label’s warnings and side-effect figures come mainly from heart-failure patients. We found no study that set out to measure shedding when starting spironolactone; the label lists hair loss (alopecia) among reported skin reactions, without a frequency.

Does it help? What commenters told people who asked

223 threads in our corpus name it in the title; nearly all are in r/tressless, a general hair-loss forum. Askers who said who they were: 58 women, 19 men and 7 trans people; 139 didn’t say. Most women asked about the pill (46 of 58); threads about the topical cream or solution (83) mostly came from people who didn’t give their gender.

61 threads asked whether it works, is worth starting, or how long it takes. In 54 a commenter answered. The main answer per thread:

  • yes, it can help: 28% (15)
  • a little, as an add-on: 2% (1)
  • it depends / answers split: 35% (19)
  • it does little, or use something else: 35% (19)

Everything commenters said, in all 223 threads

Number of threads where at least one commenter said it:

  • 53finasteride or dutasteride would do more, or should be added
  • 49men shouldn’t take it by mouth (breasts, libido, feminising)
  • 48topical spironolactone is weak or does little
  • 37see a doctor, dermatologist or endocrinologist
  • 33it is the anti-androgen in trans women’s HRT
  • 28breast tenderness or growth, or period changes
  • 26use minoxidil with it, or instead
  • 25PCOS, androgen levels or hormone tests
  • 22it helped their own hair
  • 18they took it and saw no change
  • 16lower libido or sexual side effects
  • 13dizziness, low blood pressure, peeing a lot or thirst
  • 13topical spironolactone is an option for men
  • 11not in pregnancy; use contraception
  • 11it gave them shedding or more loss
  • 10potassium, blood tests or kidneys
  • 9it takes months to judge

The most common point was a comparison: that finasteride or dutasteride would do more (53 threads). Those are the usual treatments for men; a 2025 prescribing review says they are generally not recommended for women who could still become pregnant. See what people reported on finasteride and on minoxidil.

What people said happened to their own hair

124 people (askers and commenters, each counted once) described their own use of spironolactone. What they said happened to their hair:

  • it helped their hair: 22% (27)
  • no change: 19% (24)
  • hair loss got worse: 6% (8)
  • too early to tell: 17% (21)
  • didn’t say: 35% (44)

By form: of those who took the pill, 12 said it helped and 11 saw no change or got worse; of those who used it on the scalp, 6 said it helped and 12 saw no change. Of the 29 who said they were women, 7 said it helped, 3 saw no change and 2 got worse; for the women who said how long they had taken it, the middle answer was 12 months. Many people used it together with minoxidil, finasteride, birth control or estrogen, so these are their own accounts of a whole regimen, not of spironolactone alone, and not a trial.

“it helped their hair”

“no change”

“hair loss got worse”

Does spironolactone cause hair loss or shedding?

The label lists alopecia (hair loss) among skin reactions reported with spironolactone, and says such reports can’t show how often it happens or whether the drug caused it. We found no study that measured shedding after starting it. On reddit, 12 threads were mainly about shedding: after starting, after raising the dose or after stopping. 10 of the 124 people above said they shed on it. In the 9 shedding threads where commenters answered:

  • a temporary shed, give it time: 22% (2)
  • probably something else: 67% (6)
  • split: 11% (1)

Commenters most often said it was probably something else, such as the pattern hair loss itself carrying on, or a change in birth control at the same time. These are small numbers, so they show the kinds of answers given, not how often it happens.

What askers noticed

What others said

Side effects people mentioned

32 of the 124 people named a side effect of their own, and 17 said they stopped taking it. Across all threads, commenters raised breast tenderness or growth, or period changes, in 28; lower libido in 16; dizziness, low blood pressure, peeing a lot or thirst in 13; pregnancy and contraception in 11; and potassium or blood tests in 10. These match the label and the trials: irregular periods were the most common side effect in the placebo trial (37.5% of women on it), and the label warns about high potassium, breast growth and pregnancy. On potassium, a study of 974 healthy young women taking it for acne found high readings no more often than usual; the label still tells doctors to check it.

Can men use spironolactone for hair loss?

25 threads asked whether men can or should use it. In 23 a commenter answered; the main answer:

  • yes: 4% (1)
  • a little: 4% (1)
  • only topically, or it depends: 26% (6)
  • no, not for men: 65% (15)

In 49 threads overall someone said men shouldn’t take the pill, usually naming breast growth, lower libido or feminising effects, which the label lists (about 9% of men in its heart-failure trial developed breast growth, at an average of 26 mg a day). The 2023 review gives the same reason for why nearly all the studies are in women, and a 2025 prescribing review lists spironolactone only for women, with minoxidil and finasteride or dutasteride for men. Topical spironolactone is the version discussed for men: the review calls it suitable for both sexes, but in 44 of the 83 threads about the topical form someone said it is weak or does little, against 8 where someone recommended or reported it for a man.

On the topical form

PCOS and hair loss

Many women on spironolactone also take it for acne (the potassium study above was in women taking it for acne), and PCOS came up often. In 25 threads someone brought up PCOS, androgen levels or hormone tests. The Androgen Excess and PCOS Society’s task force says every woman with pattern hair loss should be checked for androgen excess, that the hair loss alone is not a sign of it when hormone levels are normal, and that treatment should start with minoxidil, adding an anti-androgen for severe loss or high androgens.

Trans women and HRT

In 33 threads someone mentioned spironolactone as the anti-androgen in trans women’s hormone therapy, often next to estradiol. 7 people who said they were trans described their own use: 3 said their hair improved and 2 that it got worse. A 2023 review lists spironolactone 200 mg a day as a first-line hair-loss option for transfeminine patients, notes there is little research in this group, and advises the dermatologist to coordinate with the hormone prescriber.

What people reported from the main treatments: minoxidil results, finasteride results and minoxidil vs finasteride. For another drug people ask about shedding on, see GLP-1 drugs (Ozempic, Wegovy, Mounjaro) and hair loss. How spironolactone compares with the other DHT blockers: DHT blockers for hair loss. Women considering surgery: hair transplants for women. Other causes of hair loss in women, PCOS and the tests: hair loss in women.

How this page was made

We took every live reddit thread in our corpus whose title names spironolactone (in any common spelling), spiro or Aldactone, and read the asker’s post, their replies and the top comments by other people. Who asked (woman, man, trans) is counted only where the person said so; we did not guess. Each person who described their own use is counted once, even if they posted in several threads. Each quote is copied word for word from the comment or post it links to; we picked them by hand so each states the view it is shown under. Each label and study quote is copied from the archived text. Removed posts are left out, usernames are not shown, and posts that mention suicide or self-harm are never quoted. Data as of Oct 2026. This is not medical advice: spironolactone is a prescription drug, and dose, blood tests and contraception are for you and your doctor.

SaveMyHairline is an independent hair transplant doctor directory: published prices, checked credentials and real patient reports, with sources — and no clinic can pay to appear.